Rhelion Subsidiary Filament Health Signs Deal to Supply PEX010 for Linköping University Social Anxiety Trial

• Rhelion Life Sciences’ wholly owned subsidiary Filament Health signed a supply and licensing agreement with Sweden’s Linköping University for PEX010.
• The botanical psilocybin drug candidate will be supplied for PsiloSAD, a clinical trial evaluating psilocybin for social anxiety disorder.
• Linköping University sponsors the trial, led by Professor Markus Heilig.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610280800NEWSFILECNPR____20261028_321406_1) on October 28, 2026, and is solely responsible for the information contained therein.